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Microbiome dysbiosis predisposes to colorectal cancer (CRC), but a population-based 
study of antibiotic exposure and risk patterns is lacking. In this study, oral antibiotic use 
on CRC incidence was assessed. 
Methods 
A matched case-control study (incident CRC cases and up to 5 matched controls) was 
performed using the Clinical Practice Research Datalink (CPRD; January 1, 1989 to 
December 31, 2012). Conditional logistic regression was used to assess CRC association 
with oral antibiotic use, adjusting for potential confounders. Antibiotic exposure in 
categorical and continuous terms (spline) was investigated for pattern of risk, stratified by 
specific tumor location.  
Findings 
28,980 CRC cases and 137,077 controls were identified. Oral antibiotic use was 
associated with CRC risk, but effects differed by anatomic location. Antibiotic use was 
found to be associated with excess risk of colon cancer in a dose-dependent fashion 
(Ptrend<0·0001). The risk was observed after minimal antibiotic use, and was greatest in 
the proximal colon and with antibiotics with anti-anaerobic activity. In contrast, an inverse 
association was detected between antibiotic use and rectal cancers (Ptrend =0·003), 
particularly with length of antibiotic exposure >60 days (Adjusted Odds Ratio [AOR], 0·85, 
95% CI 0·79–0·93) as compared with no antibiotic exposure. Penicillins were associated 
with increased risk of colon cancer (AOR,1·09, [1·05-1·13]) whereas tetracyclines were 
associated with risk reduction for rectal cancer (AOR, 0·90, [0·84-0·97]). Significant 
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interactions were detected between antibiotic use and tumor location (colon vs rectum, 
Pinteraction <0·0001; proximal colon vs distal colon, Pinteraction =0·0194). The antibiotic-
cancer association was found for antibiotic exposure occurring >ten years before 
diagnosis (AOR, 1·17, [1·06-1·31]).   
Interpretation 
Oral antibiotic use is associated with an increased risk of colon cancer risk but a reduced 
risk for rectal cancer. This effect heterogeneity may suggest differences in gut microbiota 
and carcinogenesis mechanisms along the lower intestine tract.  
Funding 
This project was funded by Johns Hopkins Fisher Center Discovery Program and 
Bloomberg~Kimmel Institute for Cancer Immunotherapy.  
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In 2010, the estimated global consumption of antibiotics was 70 billion individual doses, 
which equates to ten doses per person, and the annual rates continue to grow steadily. 1, 
2  Given this widespread use of antibiotics, elucidating the effects of antibiotics on gut 
microbiota and links with health outcomes has substantial implications for public 
health. Use of antibiotics, even narrow spectrum antibiotics, exerts strong, persistent 
effects on the structure of the gut microbiota and impairs the integrity of intestinal barrier.3, 
4 Antibiotics allow for colonization of pathogenic microbes, 5, 6 and thus, may enable 
colonization with carcinogenic bacteria that induce local inflammation and tumor 
formation. Consistent with this hypothesis, recent data suggest differential pathogenic 
influences of the gut microbiota on neoplastic and immune cells along the colorectal 
continuum.7 
Several epidemiological studies have suggested an antibiotic-cancer association. A 
Finnish cohort study reported increased cancer risk for several cancers, including 
prostate, breast, lung and colon. 8 In a diabetic Asian population, a positive association 
between colorectal cancer (CRC) and use of anti-anaerobic agents, but not anti-aerobic 
agents was observed. 9 Yet, a study from the Netherlands found both anti-anaerobic and 
anti-aerobic agents contributed to increased CRC risk.10 The Harvard Nurses’ Health 
Study revealed an association between long-term antibiotic use in early-to-middle 
adulthood (at age 20-39 and 40-59) and excess risk of subsequent colorectal adenomas, 
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with a stronger association observed for the proximal colon adenomas, and weaker or no 
association with distal colon or rectal tumors. 11 
However, there are several limitations to the current evidence: information about known 
CRC risk factors, such as body mass index (BMI), smoking, and alcohol use, was not 
consistently measured or adjusted for across studies; a lack of sufficient power to test 
associations by tumor anatomical location, or results combined colon with rectal tumors; 
effect modification between known risk factors for CRC and antibiotics on cancer risk was 
not examined; studies with participant self-reported antibiotic use were susceptible to 
recall bias and limited in information regarding distinct antimicrobial classes and effects 
on anaerobes/aerobes; and finally, non-linear associations between antibiotics and 
cancer risk rarely have not been studied. 
Our aim was to investigate the associations between antibiotic use and site-specific 
colorectal cancer risk in the world’s largest primary care database. We hypothesized that 
antibiotic use, which targets the gut microbiota, was associated with colorectal cancer 
initiation and progression. We explored whether these effects differed by anatomic 
location.  
Methods 
Study design and setting 
We conducted a matched case-control study using data obtained from the Clinical 
Research Practice Datalink (CPRD) in the United Kingdom. The CPRD is one of the 
world's largest electronic medical record (EMR) databases of anonymized clinical records 
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with population-based data collected prospectively.12 At the time of this study, CRPD 
incorporated longitudinal medical records of 11.3 million patients from 674 practices in 
the United Kingdom (UK), representing 6.9% of the UK population.12 The details of each 
drug prescription, including dosage, instructions, and quantity, are automatically recorded 
in the computer and can be used to determine dose and duration of drug exposure. Large 
validation studies have suggested that data are of high quality for use in research.13, 14 
Participants, exposures, and outcomes 
The study population was drawn from all up-to-standard1 practices in the CPRD cohort 
from January 1, 1989 to December 31, 2012 with a minimum of two years of follow-up. 
Study entry was the start of observation, defined as patient registration date of the up-to-
standard follow-up. The date of observation end was defined as event date (CRC 
diagnosis date) both for cases and controls.  
CRC cases were identified from the clinical or referral record using a set of previously 
validated READ codes (appendix table 1) which have a sensitivity of 92%, specificity of 
99% and a positive predictive value of 98% for CRC.15 Controls were defined as patients 
without a diagnosis of CRC recorded at any time in CPRD. Up to five controls were 
randomly selected and matched to each case on: year of birth (+/-3 years), gender, 
general practitioner (GP) practice site, and year of registration in the CPRD (+/- 1 year).  
Our analysis was restricted to sporadic CRC. Thus, we excluded patients with conditions 
that predispose to CRC (inflammatory bowel disease [IBD], Peutz-Jeghers, Familial 
Adenomatous Polyposis [FAP] and Hereditary Nonpolyposis Colorectal Cancer [HNCC]). 
                                                          
1 Up-to-standard follow-up is the period of good quality data from the practice. 
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We also excluded patients with immunosuppressive states, including human 
immunodeficiency virus (HIV) infection, organ transplant and 
chemotherapy/immunosuppressive drug use because they may impact the risk of colon 
carcinogenesis. We excluded patients with anal cancers because they most commonly 
are of squamous cell origin rather than epithelial cell origin of CRC. Age was restricted 
from 40 to 90 years. We only included oral antibiotic use since the impact of intravenous 
antibiotics on the gut microbiota is largely unknown. We applied the same exclusion 
criteria to the controls. For those patients who had an identifiable tumor location, tumors 
originating from the caecum, ascending colon, hepatic flexure, and transverse colon were 
classified as those of the proximal colon, whereas splenic flexure, descending, or sigmoid 
colon tumors were classified as those of the distal colon. Tumors in the rectum or at the 
rectosigmoid junction were classified as rectal location (appendix table 1).  
We quantified antibiotic exposure by calculating the cumulative number of days they were 
prescribed, as well as the total number of prescriptions written during research-standard 
CPRD follow-up (from registration date to one year before CRC diagnosis). Antibiotics 
were categorized based on their action effects on aerobes/aerobes, as well as by drug 
class (cephalosporins, macrolides, penicillins, quinolones, sulpha/trimethoprim, 
tetracyclines, and others, appendix table 2). Timing preceding CRC was categorized as 
exposure occurring in the biologically plausible thresholds 1-10 years and >10 years.  
Statistical analysis 
Conditional logistic regression was used to estimate ORs and 95% CIs for the risk of 
incident CRC in relation to antibiotic use. In the main analysis, antibiotic exposure was 
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evaluated by number of days and by known therapeutic anaerobic effect (yes/no), and 
class of antibiotics across anatomic site (colon vs rectum; proximal vs distal colon), 
controlling for BMI, smoking status, alcohol use, history of diabetes diagnosis, and 
number of colonoscopies received. For time-varying covariates (BMI, smoking status and 
alcohol use), values were assigned using previously described methods 16 (i.e., use of 
the earliest records available during research-standard CPRD follow-up, or the most 
recent previous records if individuals lacked records at the beginning of research-
standard follow-up; older values were dropped in a subsequent sensitivity analysis). We 
initially characterized antibiotic use in days as categorical terms (0 days, 1-15 days, 16-
30 days, 31-60 days and >60 days) to quantify the average effect of each duration 
increase on CRC risk. To test for trend in the risk of CRC across different categories of 
length of prescription, we included the antibiotic categories as a continuous variable in 
the adjusted model. We then fitted fully adjusted models with a restricted cubic spline by 
taking the number of days of antibiotic use as a continuous term to assess possible non-
linearity in any detected antibiotic-cancer association overall and by tumor location. Effect 
modification was evaluated by introducing interaction terms (one at a time) between 
antibiotic use and location (colon vs rectum, and proximal colon vs distal colon), as well 
as known risk factors for CRC including BMI, smoking status, alcohol use, and diabetes 
history to the full model. In order to examine the temporal relationship between CRC and 
antibiotic exposure, we analyzed antibiotic use with time preceding diagnosis of 1-10 
years and >10 years among patients with at least 15 years of follow-up. For missing data 
on BMI, smoking status, and alcohol use, we employed multiple imputation to impute the 
missing data by using chained equations with ten imputed datasets assuming that BMI, 
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alcohol, and smoking were missing at random,17 as well as by including missing values 
as a category in each variable in the fully adjusted model.18 
In sensitivity analyses, we excluded CRC cases occurring within one year after 
registration to address concerns of possible prevalent cases at study entry, included only 
lifestyle factors recorded during follow-up period, included only antibiotic prescriptions 
more than 3 years prior to CRC diagnosis to guard against reverse causality (i.e., 
antibiotic use being affected by undiagnosed CRC), and  assigned transverse colon cases 
to distal colon instead of  proximal colon. In addition, we assessed how different 
categorization of antibiotic anti-anaerobic and anti-aerobic effects impact CRC risk. The 
categorizations assessed were (appendix table 3): 1) a restricted list of agents with 
predominant anti-anaerobic or anti-aerobic effects, 2) exclusion of vancomycin from the 
anaerobic antibiotic list, 3) categorization of cephalosporins as anti-anaerobic antibiotics, 
4) categorization of ampicillin/amoxicillin as anti-aerobic antibiotics, 5) exclusion of 
cephalosporins from the anti-aerobic antibiotic list, and 6) assessment of amoxicillin, the 
most commonly used oral antibiotic, as an anti-aerobic antibiotic agent, to test if the 
impact of amoxicillin alone on the results.  
This study was approved by the Institutional Review Board of the Johns Hopkins 
University. Statistical analyses were performed using Stata/MP 15. 1 (StataCorp, College 
Station, TX). All tests of significance used two-sided p-values at the p<0.05 level. 
Role of the funding source 
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The funders of the study had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. The corresponding author had full access to all the 
data in the study and had final responsibility for the decision to submit for publication. 
Results 
In the CPRD, 28,980 eligible CRC cases and 137,077 matched controls were identified 
using the selection algorithm (Figure 1). Participants with CRC were more likely to be 
overweight (35·2% vs 33·8%) and obese (18·6 vs 16·4%), to have history of smoking 
(49·9% vs 46·9%), have moderate-heavy alcohol use (13·8% vs 11·4%) , have diabetes 
history (8·8% vs 7·7%), and to undergo colonoscopy (3·5% vs 2·9%), and less likely to 
have chronic NSAID use (7·2% vs 9·0%) compared to the control group. As compared to 
participants with rectal cancer, those with colon cancer were more likely to be female 
(46·9% vs 39·2%), overweight-obese (44·9% vs 41·5%), smokers (49·3% vs 46·9%), 
alcohol users (74·0% vs 72·6%), have a diabetes history (9·1 % vs 8·2%), and to undergo 
colonoscopy (3·9% vs 2·6%) compared to those with rectal cancer (Table 1 and Appendix 
Table 4).  
 
Participants had a median follow-up of 8·1 years (Interquartile range [IQR], 4·9-12·3 
years), Antibiotics had been prescribed to 20,278 (70·0%) CRC cases and 93,862 
(68·5%) controls (P<0·001). Participants who subsequently developed colon cancers 
were more likely to be exposed to antibiotics as compared with controls (71·3% vs 69·1%, 
P<0·001), whereas participants with rectal cancers had comparable exposure to 
antibiotics (67·1% vs 67·2%, P=0·96). Both anti-anaerobic antibiotics and anti-aerobic 
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antibiotics were more likely to be prescribed in cases who subsequently developed colon 
cancer cases relative to controls, yet rectal cancer cases had less anti-aerobic antibiotic 
exposure than controls (Table 2). Of those with known CRC location, participants with 
proximal colon cancers were more likely to have antibiotic exposure, particularly those 
with anti-anaerobic effects, whereas participants with distal colon cancers had similar 
antibiotic exposure compared to controls, regardless of antibiotic spectrum (appendix 
Table 5). The most common prescriptions for antibiotics were penicillins (80·7%), 
macrolides (30·4%), sulpha and trimethoprim (28·9%), cephalosporins (25·1%), 
tetracyclines (20·3%) and quinolones (14·3%).  Most participants (59·5%) were exposed 
to more than one antibiotic class. By antibiotic class (any vs. none), participants with colon 
cancers had increased use of cephalosporins and quinolones, whereas those with rectal 
cancers received fewer prescriptions for tetracyclines and macrolides (Table 2).  
 
Use of any antibiotics was associated with CRC risk compared with non-use, but the 
effect size and pattern across antibiotic exposure category differed by tumour location 
(Figure 2 and Figure 3). In the colon, excess risk was observed with increased use of 
antibiotics in a dose-dependent fashion, with no use as the reference (1-15 days/16-30 
days/31-60 days/>60 days vs non-users, AORs: 1·08 [1·04–1·13]/1·14[1·08–
1·20]/1·15[1·09–1·22]/1·17[1·10-1·23]; Ptrend<0·0001), adjusted for BMI, smoking, alcohol 
use, diabetes status, chronic NSAID/aspirin use, and number of colonoscopies. The effect 
of antibiotic use on cancer risk was more marked in the proximal colon (1-15 days/16-30 
days/31-60 days/>60 days vs non-users, AORs: 1·14 [1·02–1·28]/1·15[1·01–
1·32]/1·32[1·15–1·51]/1·09[0·94-1·25]; Ptrend= 0·046), whereas no association was 
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observed for each of the exposure categories on distal colon cancer risk (all P>0·10, 
Ptrend= 0·40). In the rectum, use of antibiotics showed an inverse association with CRC, 
with a maximum risk reduction of 15% for antibiotic use exceeding 60 days, as compared 
with non-use (AOR, 0·85, 95% CI 0·79–0·93, Ptrend=0·003, Figure 2).  
 
Antibiotics with anti-anaerobic action properties were associated with an increased colon 
cancer risk (Ptrend<0·001), particularly in the proximal colon (Figure 4, appendix Figure 1, 
and appendix Figure 2). An inverse association with antibiotic exposure was observed for 
rectal cancer, regardless of effects on anaerobes (agents with anti-anaerobic activity, 
Ptrend =0.015, agents with anti-aerobic activity, Ptrend =0.005). By antibiotic class, use of 
penicillins was associated with an increased colon cancer risk (AOR 1·09, [1·05–1·13]), 
particularly in the proximal colon, but not cephalosporins, quinolones, macrolides, or 
sulpha/trimethoprim (appendix Figure 1). In contrast, tetracycline use decreased rectal 
cancer risk (AOR, 0·90, [0·84-0·97], appendix Figure 1).  
 
Figure 5 shows the adjusted non-linear pattern of antibiotic-cancer association by tumor 
location. For colon cancers, exposure to antibiotics was associated with substantially 
increased risk, with the effect increased after minimal antibiotic use and plateaued after 
60 days of cumulative exposure.  Antibiotics were associated with an increased proximal 
colon cancer risk at minimum exposure levels but antibiotics were not associated with risk 
of distal colon cancer. For rectal cancer, there was a reduced risk of cancer associated 
with cumulative exposure to any antibiotic; however this effect was not observed until 
after 30 days of cumulative exposure and plateaued after 90 days (Figure 5). Significant 
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interaction was found between antibiotic use and tumor location (colon vs rectum) 
(Pinteraction<0·0001), as well as between antibiotic use and location in the colon (proximal 
colon vs distal colon) (Pinteraction =0·0194). No interactions were observed between the use 
of antibiotics and known risk factors for CRC (BMI, smoking status, alcohol use, and 
diabetes history, all P>0·10) at each anatomical location. 
 
Limiting the analysis to participants with at least 15 years of follow-up, use of antibiotics 
for more than 10 years before the cancer diagnosis was associated with an increased 
colon cancer risk (AOR, 1·17, [1·06-1·31]) as compared to non-antibiotic users, whereas 
antibiotic use 1-10 years before cancer diagnosis was not associated with colon cancer 
risk (AOR, 1·00, [0·89-1·10]); no association was found between use of antibiotics and 
rectal cancer risk by time window (>10 year users vs non users, AOR: 0·98, [ 0·84-1·13]; 
1-10 year user vs non users, AOR:0·93, [0·91-1·09]).  
 
Our main findings were robust to a range of sensitivity analyses (appendix Tables 6-9). 
When ampicillin/amoxicillin was considered as a primarily anti-aerobic antibiotic, the 
effects from anti-anaerobic and anti-aerobic agent exposure on colon cancer risk 
inverted, (appendix Figure 2-3) suggesting this class of antibiotics was the dominant 
contributor to the outcomes presented.  
 
Discussion  
In this largest analysis of antibiotic-CRC association to date, we demonstrated that use 
of oral antibiotics associated with CRC risk, but the effect size and pattern of risk varied 
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by anatomical location in the colorectum. A dose-dependent increase in colon cancer risk 
was observed for any antibiotic use. This positive association was driven by anti-
anaerobic antibiotics and was limited to the proximal colon, with risk increased after 
minimal antibiotic use. However, a reduced cancer risk from antibiotic exposure was 
shown in the rectum. Penicillin exposure was strongly associated with increased colon 
cancer risk, whereas an inverse association was found with rectal cancer for tetracyclines. 
The association between antibiotic exposure and colon cancer was seen in participants 
with required antibiotic exposure more than ten years prior to CRC detection.  
 
Several studies suggest an increased risk for CRC or colorectal adenoma from antibiotic 
use.8, 10, 11, 19 Our results add to this evidence base by systematically investigating the 
dose-response relationships by tumor location, antibiotic action against 
anaerobes/aerobes, and by antibiotic classes. These analyses, which examined linear 
and non-linear effects along with evaluation of effect modification by known risk factors 
for CRC, enhance the understanding of the antibiotic-cancer association.  
 
Results from this study were broadly consistent with previous reports (appendix table 
10). We extended previously reported antibiotic-colon cancer associations by observing 
that the dose-response pattern is non-linear and can increase with even a single 
antibiotic course but plateaus after 60 cumulative days. Consistent with previous 
studies, penicillins were associated with significantly increased colon cancer risk.10, 19 
We additionally demonstrated that a penicillin-cancer association was only detected in 




We uniquely showed a protective role of antibiotics for rectal cancer, especially 
tetracyclines. This contrasts with those reports of a null or positive association, which 
could have been due to limited sample size and combined analyses of rectal cancers with 
colon cancers.9, 11 Several studies have reported the anti-inflammatory effects of 
tetracyclines and their potential anti-neoplastic role. 20, 21 However, this association needs 
to be confirmed in other large cohorts and through mechanistic studies for additional 
validation.  
 
In our study, the effect on CRC risk was most significant after oral exposure to anti-
anaerobic agents, which markedly disrupt the microbiota organization and structure in the 
colon since the gut microbiota is predominately composed of anaerobes. It is possible 
that the disrupted microbiota enables acquisition or development of a carcinogenic colon 
microbiota. Previous data have suggested that not only select bacteria but a select 
consortium may contribute to colon carcinogenesis.7, 22-24  
While the exact mechanism of differential antibiotic-cancer association by anatomic 
location is unknown, it is possible that putative carcinogenic bacteria, such as 
Fusobacterium, Porphyromonas, Enterococcaceae, and Bacteroides–Prevotella, as well 
as toxin-producing species including some B. fragilis and E. coli, may be differentially 
distributed along the colorectal tract or that colon epithelial cells display differing regional 
sensitivity to the microbiota. For example, Fusobacterium nucleatum, that is associated 
with a subset of CRC, was reported in one study to decrease in a gradient fashion from 
cecum to rectum, with proximal colon cancers harboring the highest F. nucleatum levels.7 
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A recent meta-analysis using high-resolution bacterial 16S rRNA gene profiling did not 
confirm this pattern, but did identify an association between a small consortium of bacteria 
(a symbiont with capacity for tumorigenesis [Bacteroides fragilis], and oral pathogens 
including Fusobacterium nucleatum, Parvimonas micra, Gemella morbillorum) and CRC 
risk.24 CRC tissues were enriched for polymicrobial invasive biofilms, particularly on right-
sided tumors.24 Thus, the greater antibiotic impact on the proximal colon may reflect 
disruption of biofilm formation that have been linked with procarcinogenesis.23, 25 
Additionally, the emergence of data showing differential frequencies of tumor molecular 
characteristics, subsite-specific clinicopathological differences, and response to 
treatment implies that the development of proximal colon, distal colon and rectal cancers 
differ mechanistically. 26  
There are several strengths to a study of this breadth. This is the first use of the CRPD to 
facilitate compiling the largest CRC cohort with matched cases and controls and available 
high-quality data on the use of antibiotics, lifestyle factors (BMI, smoking, alcohol use), 
comorbidity as well as other medications. We were able to investigate the relationships 
between antibiotics and CRC with greater precision and power than has been previously 
described, controlling for potential confounders. Second, in the UK, registration with a 
primary care GP is essentially universal (> 98%), enabling prospective and unbiased 
collection of longitudinal clinical data in CPRD, with almost all (99·7%) prescriptions 
recorded.27 Data from CPRD are largely representative of the UK population and results 
are thought to be generalizable to the UK population and to comparable countries. Third, 
we systematically examined the possible non-linearity and effect modification of an 
antibiotic-cancer association and provide additional evidence for microbiota causality in 
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CRC development. Further, availability of information regarding the cancer location, dose 
and classes of antibiotics provided insights to the heterogeneity of the antibiotic-cancer 
association and implied differences in microbiota mechanisms along the GI tract.  
There are several limitations for our study. First, potential residual confounding may still 
exist despite adjustment for known risk factors associated with CRC. Second, missing 
data for life-style factors ranged from 10~20%. However, we employed two approaches 
to deal with missingness, and obtained consistent results. Third, data not captured in 
CPRD include prescriptions in secondary care, prescriptions filled, and treatment 
adherence. Certain patient groups are missing from primary care records, such as 
prisoners, private patients, some residential homes and the homeless, and we excluded 
individuals with immune-deficient conditions; thus interpretation with respect to those 
populations is limited. In addition, CPRD does not have information on food intake, 
physical activity and family history that may influence CRC risk. Fourth, the number of 
patients with recorded Read codes specifying whether the colon cancer was located in 
the proximal vs distal colon was limited; thus, analyses in these anatomical groups may 
be underpowered and results should be interpreted with caution. Lastly, misclassification 
of antibiotic effect on anaerobes and by antibiotic class may exist. To test these 
associations, we employed several sensitivity analyses comparing therapeutic anti-
anaerobic and anti-aerobic antibiotics and analyzed how specific drugs may change/drive 
the effect size and pattern and results showed consistency with our main analysis. 
In conclusion, our results provide evidence supporting a potential causal relationship 
between antibiotic-induced microbiome dysbiosis, which may influence subclinical 
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mucosal inflammation, and colon tumor formation. Substantial heterogeneity in the 
magnitude and pattern of antibiotic effects exist anatomically in the colon consistent with 
different microbial-driven mechanisms of cancer pathogenesis occurring along the GI 
tract. More clinical and translational studies are warranted to test the interplay of 
antibiotics of different activities and class on the colonic anaerobic and aerobic microbiota 
and mechanisms of carcinogenesis.  
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